Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 581 for:    reduced glutathione

Sublingual L-GSH Supplementation in Male Subjects With Smoking Habit and/or Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02125045
Recruitment Status : Completed
First Posted : April 29, 2014
Last Update Posted : May 8, 2014
Sponsor:
Information provided by (Responsible Party):
Niguarda Hospital

Brief Summary:

Background. The antioxidant systems are the main endogenous defense against free radicals, and glutathione seems to play an important role in this mechanism. Reduced glutathione enters into the detoxification processes of endogenous products, such as hydro- and lipoperoxides and exogenous compounds such as pollutants, heavy metals and some drugs. Changes in GSH homeostasis have been implicated in the etiology and progression of several diseases. Supplementation of GSH may improve the endogenous antioxidant defense and may contribute to decrease of oxidants tissue damage a pathophysiologic mechanism of many acute and chronic diseases.

However, the efficacy of GSH treatment seems to be closely related to the degree of its absorption and to the increase of its concentrations in plasma and cells. Previous studies of oral GSH administration in healthy volunteers or in patients failed to find any effect in terms of oxidative stress reduction and/or disease improvement because the GSH is quickly catabolized by gastrointestinal tract. We have recently observed (preliminary data) that a new sublingual formulation of L-GSH (OXITION), produced by PH&T S.r.l., is able to increase erythrocyte and plasma GSH levels in healthy volunteers bypassing gastrointestinal barrier.

Objectives. The primary study objective is to determine whether medium term (4 weeks) of sublingual L-GSH supplementation to a population with smoking habit and/or arterial hypertension may result in improved endothelial function as assessed by the flow mediated dilation (FMD) technique versus placebo. FMD is a surrogate end point validated in the literature as prognostic predictor for major cardiovascular events in patients with endothelial dysfunction. Secondary study objectives are to determine differences between the 2 treatment in terms of oxidative stress markers.

Methods. This is a phase 3, double-blind, randomized, placebo-controlled, cross-over study performed in only one centre. Sixteen male subjects, aged ≥ 40 and ≤ 60 years, with smoking habit and/or hypertension defined as arterial blood pressure ≥ 140 and/or 90 mmHg or in anti-hypertensive treatment, will be enrolled and randomized to receive sublingual L-GSH (100 mg twice a day) or placebo according to a double-blind cross-over design for 4 weeks with a 3-week wash-out period between the two treatments. Baseline and at the end of each treatment period, FMD assessment and blood samples collection for routine (creatinine, urea, AST, ALT GGT, total cholesterol, HDL, LDL, triglycerides, fasting glucose) and specific (aminothiols, nitrotyrosine, malondialdehyde, 8-hydroxy-deoxyguanine) biochemical determination will be performed.


Condition or disease Intervention/treatment Phase
Health Subjects With Cardiovascular Risk Factors Dietary Supplement: L-GSH Dietary Supplement: Placebo Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Medium Term Effect of Sublingual L-glutathione (L-GSH) Supplementation on Flow Mediated Dilation and Oxidative Stress Markers in Male Subjects With Smoking Habit and/or Arterial Hypertension
Study Start Date : February 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: L-GSH
Glutathione 100 mg tablets twice a day
Dietary Supplement: L-GSH
Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.

Placebo Comparator: Placebo
Matching placebo will be administered for 4 weeks in a double blind fashion.
Dietary Supplement: Placebo
Placebo will be prepared using the same excipients of the dietary supplement without active substance.




Primary Outcome Measures :
  1. endothelium-dependent vasodilation [ Time Frame: Baseline and at 1 month after placebo or L-GSH treatment ]
    Registration of pulsatile blood volume in the fingertips of both hands will be assessed by a non invasive plethysmographic method (Endo-PAT2000, Itamar Medical Ltd., Caesarea, Israel) system. Endo-PAT device consists of two finger-mounted probes, which include a system of inflatable latex air-cushions within a rigid external case. The probe design allows the application of a constant and evenly distributed near-diastolic counterpressure within the entire probe, which increases sensitivity by unloading arterial wall tension, and prevents venous blood pooling to avoid venoarteriolar reflex vasoconstriction. Pulsatile volume changes of the fingertip are sensed by a pressure transducer and transferred to a personal computer where the signal is band pass-filtered (0.3 to 30 Hz), amplified, displayed, and stored.


Secondary Outcome Measures :
  1. Oxidative stress markers [ Time Frame: Baseline and at 1 month after placebo or L-GSH treatment ]
    Screening (V-1 - day -1): eligibility assessment; Baseline 1 (V0 - day 0): informed consent, interview, vital signs (blood pressure and heart rate), routine biochemistry (serum fasting glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, creatinine, urea, gamma-glutamyl-transpeptidase, aspartate-amino transferase, alanine-amino transferase), specific biochemistry (total and reduced blood glutathione, plasma nitrotyrosine, plasma malondialdehyde and plasma 8-hydroxy-2'-deoxyguanosine) flow-mediated dilation (FMD) assessment, randomization and dispense drug (L-GSH or placebo - 100 mg b.i.d.); Follow-up 1 (V1 - week 4): vital signs, routine biochemistry, specific biochemistry, FMD, adverse events; Baseline 2 (V2 - week 7/8): interview, vital signs, routine biochemistry, specific biochemistry, FMD and dispense drug (L-GSH or placebo - 100 mg b.i.d.); Follow-up 2 (V3 - week 11/12): vital signs, routine biochemistry, specific biochemistry, FMD, adverse events


Other Outcome Measures:
  1. Adverse events [ Time Frame: after 4, 8 and 12 weeks from the first visit V0 ]
    The safety will be assessed by monitoring the adverse effects related with the administration of LGSH or placebo



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • informed consensus
  • age from 40 to 60 years,
  • without any signs or symptoms of cardio-cerebro-vascular event at the enrolment,
  • smokers (>10 cigarette/die from almost 1 year)
  • arterial hypertension (PAS≥140 mmHg and/or PAD≥90 mmHg or in anti-hypertensive treatment)

Exclusion Criteria:

  • chronic assumption of acetylsalicylic acid and/or statins
  • obesity defined as BMI ≥30 kg/m2
  • diabetes mellitus defined as fasting glycemia >126 mg/dL
  • dyslipidemia defined as LDL >155 mg/dL
  • chronic renal dysfunction with Glomerular Filtration Rate<60 mL/min/1.73 m2
  • in acetylcysteine treatment or with any other GSH-related molecules supplementation
  • in vitamins supplementation or with other compounds derived from red rice (ARMOLIPID or similar).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02125045


Locations
Layout table for location information
Italy
Oberdan Parodi, MD
Milan, Italy, 20162
Sponsors and Collaborators
Niguarda Hospital
Investigators
Layout table for investigator information
Study Director: Jonica Campolo, MSc Insitute of Clinical Physiology CNR
Study Chair: Gianpalolo Micheloni, MD Niguarda Ca' Granda Hospital

Layout table for additonal information
Responsible Party: Niguarda Hospital
ClinicalTrials.gov Identifier: NCT02125045     History of Changes
Other Study ID Numbers: 215_062013
First Posted: April 29, 2014    Key Record Dates
Last Update Posted: May 8, 2014
Last Verified: May 2014

Keywords provided by Niguarda Hospital:
GSH
cardiovascular risk factors
endothelial dysfunction
oxidative stress

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases